1 **Use of heated tobacco products may be associated with hypertensive disorders of**
2 **pregnancy and low birth weight in Japan: An analysis of the JACSIS study**

3

4 Masayoshi Zaitzu,^{1,*} Yoshihiko Hosokawa,^{1,2,*} Sumiyo Okawa,³ Ai Hori,⁴ Gen Kobashi,¹
5 Takahiro Tabuchi³

6

7 ¹ Department of Public Health, School of Medicine, Dokkyo Medical University, Tochigi,
8 Japan

9 ² Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba,
10 Ibaraki, Japan

11 ³ Cancer Control Center, Osaka Medical Center for Cancer and Cardiovascular Diseases,
12 Osaka, Japan

13 ⁴ Department of Global Public Health, University of Tsukuba, Tsukuba, Ibaraki, Japan

14 * These authors contributed equally to this work.

15

16 **Corresponding author:** Masayoshi Zaitzu, MD, PhD

17 Department of Public Health, School of Medicine, Dokkyo Medical University

18 880 Kitakobayashi, Mibu, Shimotsuga-gun, Tochigi, 321-0293 Japan

19 Tel: +81-282-87-2133; Fax: +81-282-86-2935

20 Email: m-zaitzu@dokkyomed.ac.jp

21 ORCID: orcid.org/0000-0001-7616-355X

22

23 **Word count:** 2213

24 **What this paper adds:**

- 25 ● Little is known about heated tobacco product (HTP) use and associated
- 26 perinatal risks among pregnant women.
- 27 ● In Japan, the prevalence of ever HTP use exceeded 10% among pregnant
- 28 women.
- 29 ● HTP use approximately doubled perinatal risk of hypertensive disorders of
- 30 pregnancy and low birth weight.
- 31 ● When stratified by cigarette smoking status, a similar tendency was observed
- 32 among never and ever cigarette smokers.

33

34 **ABSTRACT**

35 **Background:** Little is known about heated tobacco product (HTP) use in pregnant women
 36 and associated maternal and neonatal risks for hypertensive disorders of pregnancy (HDP)
 37 and low birth weight (LBW). Thus, this study aimed to assess the status of HTP use among
 38 pregnant women in Japan and explore the risk of HDP and LBW associated with HTP use.

39 **Methods:** Using data from the Japan “COVID-19 and Society” Internet Survey (JACSIS)
 40 study, a web-based nationwide survey, we investigated 558 post-delivery and 365 currently
 41 pregnant women in October 2020. We assessed the prevalence of ever HTP smokers (defined
 42 as ever experiencing HTP use) in post-delivery and currently pregnant women. Among post-
 43 delivery women, we collected the information regarding HDP and LBW based on their
 44 Maternal and Child Health Handbooks (maternal and newborn records). In the multivariable
 45 regression analysis, we estimated the adjusted odds ratios (ORs) and 95% confidence
 46 intervals (CIs) of ever HTP smokers for HDP and LBW compared with those of never HTP
 47 smokers using logistic regression. A stratified analysis with respect to combustible cigarette
 48 smoking (never/ever) was also performed.

49 **Results:** The prevalence of ever HTP use were 11.7% and 12.6% in post-delivery and
 50 currently pregnant women, respectively. Among post-delivery women, ever HTP smokers
 51 had higher HDP incidence (13.8% vs. 6.5%, $P=0.03$), with an OR of 2.78 (95% CI 0.84–
 52 9.15) and higher LBW incidence (18.5% versus 8.9%, $P=0.02$), with an elevated OR of 2.08
 53 (95% CI 0.80–5.39). A similar tendency was observed among never and ever combustible
 54 cigarette smokers.

55 **Conclusion:** In Japan, the incidence of HTP use has exceeded 10% among pregnant women,
 56 and HTP smoking may be associated with increased maternal and neonatal risks. School-
 57 based tobacco prevention and cessation programs should be conducted regardless of product
 58 types to prevent life-threatening perinatal complications and deaths.

59 **Keywords:** heated tobacco products, hypertensive disorders of pregnancy, COVID-19,
60 smoking, preconception

61

62 INTRODUCTION

63 The widespread use of heated tobacco products (HTPs) is an emerging public health
64 concern.[1] Since the initial marketing of HTPs in 2014, the prevalence of HTP use has
65 increased in Japan, exceeding 15% in the young population aged 20–39 years in 2019,[2] and
66 this incidence was maintained over 15% during the coronavirus disease (COVID-19)
67 pandemic in 2020.[3]

68 Although the impression of HTPs as a healthy alternative to combustible cigarettes is
69 promoted by the advertising of HTPs (e.g., reduced harmfulness and a smoke-free image),[4]
70 HTP-related unfavorable health outcomes, including acute respiratory and cardiovascular
71 risks, are likely to occur.[5, 6] However, little is known about HTP use and associated
72 maternal and neonatal risks in pregnant women, including hypertensive disorders of
73 pregnancy (HDP) and low birth weight (LBW).[7, 8] Although some controversial
74 associations have been reported for HDP with respect to combustible cigarettes,[9] this type
75 of cigarettes increases various maternal and neonatal risks in Japan.[10, 11] Therefore, we
76 hypothesized that HTP use is associated with HDP and LBW, regardless of combustible
77 cigarette smoking.

78 This study aimed to assess the status of HTP use among pregnant women in Japan and
79 explore the risk of HDP and LBW associated with the use of HTP by analyzing data from a
80 nationwide web-based survey in Japan that contained pregnancy-related information and data
81 related to behavioral factors (e.g., HTP use and combustible cigarette smoking), and social
82 background.

83

84 MATERIALS AND METHODS

85 Data setting

86 This cross-sectional internet-based study is part of the Japan COVID-19 and Society Internet
87 Survey (JACSIS) study. The JACSIS study comprises three surveys in the following three
88 target populations: (a) young people and adults aged 15–79 years, (b) currently pregnant and
89 post-delivery women, and (c) adults living in a single-parent household. The study samples
90 for each survey were retrieved from the pooled panels of an internet research agency
91 (Rakuten Insight, Inc., which had approximately 2.2 million panelists in 2019).[12] We used
92 data from currently pregnant and post-delivery women, which were collected in October
93 2020.

94 The internet research agency identified 21,896 eligible women, randomly selected 4373
95 women who gave birth after October 2019 or who were expected to give birth by March
96 2021, and distributed the questionnaire comprising 61 questions to the selected women
97 through a designated website. Next, we collected data from 1000 women (response rate,
98 22.9%) stratified by delivery date as follows: (a) 600 post-delivery women who delivered
99 during October 2019–March 2020 (n=200), April–May 2020 (n=200), and June–October
100 2020 (n=200) and (b) 400 currently pregnant women who were expected to deliver during
101 October 2020–March 2021. Among 1000 study participants, we excluded 77 who provided
102 irrelevant or conflicting information (45 post-delivery and 32 currently pregnant women) as
103 done in previous studies of the same research agency,[13] yielding a total of 923 study
104 participants for the analysis (558 post-delivery and 365 currently pregnant women). Informed
105 consent was obtained electronically, and the Institutional Review Board of the Osaka
106 International Cancer Institute approved the study (Protocol Number 20084).

107

108 Definition of HDP and LBW

109 Data on HDP and LBW were extracted from the web-based self-reported questionnaires. We
110 defined the incidence of HDP based on whether the study participants had been diagnosed as

having HDP or preeclampsia during pregnancy. The criteria for HDP diagnosis in Japan were derived from the criteria of the American College of Obstetricians and Gynecologists (i.e., systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg after the 20th week of gestation).[14] We defined the incidence of LBW on the basis of the diagnosis of LBW (birth weight < 2500 g).

All participants were asked to provide information from their Maternal and Child Health Handbooks. In brief, as previously described,[15, 16] the Maternal and Child Health Handbooks are well-established integrated home-based records of maternal, newborn, and child health. As a part of a national maternal and child health policy, all municipalities issue a handbook to all women who report a pregnancy, and medical professionals record the health information of the mother and child, including clinical outcomes (e.g., blood pressure and birth weight) and incident diagnoses (e.g., HDP and LBW) during pregnancy. Mothers seldom lose their Maternal and Child Health Handbooks (losing rate, $< 1\%$).[15]

HTP and cigarette smoking and other covariates

In the questionnaire, study participants were asked to indicate their smoking status (never, once or a few times but not habitually, former, sometimes, or every day) for each HTP available in the study period (Ploom Tech, Ploom Tech plus, Ploom S, IQOS, glo, glo sens, and PULZE). If they answered “never” for all HTPs, we defined them as never HTP smokers; the remaining participants were considered ever HTP smokers.

We also classified the status of combustible cigarette smoking (never/ever). For other covariates, we included age, educational attainment (≤ 12 years [high school] or ≥ 13 years [college or university]), occupation (manager or others), household income (< 2 million JPY [approximately 20,000 USD], 2 to < 6 million JPY, and ≥ 6 million JPY), and comorbidity (having hypertension or diabetes).[17]

136

137 **Statistical analysis**

138 Descriptive statistics were computed, and t-test or chi-squared test was performed. We
139 assessed the prevalence of ever HTP smokers among post-delivery and currently pregnant
140 women. Additionally, we described detailed HTP smoking status cross-classified according
141 to the combustible cigarette smoking status of currently pregnant and post-delivery women.

142 To assess the potential association between HTP smoking and perinatal risk of HDP
143 and LBW, we restricted the sample to 558 post-delivery women who could complete all the
144 assessments during their pregnancy (Table 1). In the multivariable logistic regression
145 analyses, the odds ratio (OR) and 95% confidence interval (CI) of ever HTP smokers for
146 HDP risk were estimated with adjustment for age (model 1, the main model in the present
147 study). The reference group comprised never HTP smokers. In model 2, we fully adjusted for
148 other explanatory variables (combustible cigarette smoking, educational attainment,
149 occupation, household income, and comorbidity) and excluded 64 participants with missing
150 information on household income. The same analyses were performed for LBW. For
151 sensitivity analysis, we conducted a stratified analysis with respect to combustible cigarette
152 smoking (never/ever).

153 Alpha was set at 0.05, and all *P*-values were two sided. Data were analyzed using
154 STATA/MP13.1 (StataCorp LLC, College Station, TX).

155

156 **RESULTS**

157 Among 558 post-delivery women, the incidences of HDP and LBW were 7.3% (n=41) and
158 10.0% (n=56), respectively, and the prevalence of ever HTP smokers was 11.7% (n=65,
159 Table 1). Furthermore, among 365 currently pregnant women, the prevalence of ever HTP
160 smokers was 12.6% (n=46), which did not differ from that of HTP smokers among post-

delivery women ($P=0.66$). Among currently pregnant women, 4.4% of former combustible cigarette smokers reported smoking HTPs during pregnancy (Table 2), corresponding to 1.1% (4 out of 365) of current HTP smokers.

Among post-delivery women, the HDP incidence was higher in ever HTP smokers than in never HTP smokers (13.8% vs. 6.5%; Table 1). Similarly, the incidence of LBW was higher among ever HTP smokers than among never HTP smokers (18.5% vs. 8.9%, Table 1). When stratified by combustible cigarette smoking, a similar tendency was observed among never and ever combustible cigarette smokers (Table 1).

In the regression analysis, the age-adjusted ORs for HDP and LBW were elevated in ever HTP smokers (model 1, Figure 1); the ORs for HDP and LBW were 2.48 (95% CI, 1.11–5.53) and 2.36 (95% CI, 1.16–4.78), respectively. Although the elevated ORs were attenuated after fully controlling for other covariates, the tendency remained elevated (model 2, Figure 1). In the same regression analyses (model 2), while ever combustible cigarette smokers did not predict perinatal outcomes, managerial workers predicted the incidence of HDP and LBW; the ORs for HDP and LBW were 3.92 (95% CI 1.16–13.2) and 3.74 (95% CI 1.41–9.93), respectively. When stratified by combustible cigarette smoking, a similar tendency was observed independently in never and ever combustible cigarette smokers (Figure 1). For instance, among never combustible cigarette smokers, the age-adjusted OR of HTP use for LBW was 4.82 (95% CI, 1.19–19.6).

DISCUSSION

During the COVID-19 pandemic in Japan, the incidence of HTP use among pregnant women is likely to exceed 10%, and we found that HTP use may be associated with perinatal risk of HDP and LBW. Although the impact was attenuated after controlling for other potential explanatory factors and the significance disappeared due to weak statistical power, the

maternal risk might be high independent of combustible cigarette smoking. This result seems to be reliable because the incidence estimate of approximately 7% HDP found in our study (using Maternal and Child Health Handbooks) is consistent with the general statistics reported for Japanese pregnant women.[14] In addition, pregnant women of high socioeconomic status independently predicted the risk of HDP, which might also support our findings because they are known to use HTP more frequently than women of lower socioeconomic status.[17]

We also found that LBW, a well-known smoking-related neonatal risk,[18] was associated with HTP use. In fact, the incidence of HTP use doubled the risk of LBW, and the association was stronger among never combustible cigarette smokers. These results seem to be reliable because the incidence estimate of approximately 10% LBW found in our study (using Maternal and Child Health Handbooks) is consistent with the general statistics reported for Japanese pregnant women.[19] This also implies that aerosols of HTPs containing nicotine and other inhalable substances can cause acute adverse health events on the development of infants.

To the best of our knowledge, this is the first report of a potential association between HTP use and perinatal risks. Although smoking plays a controversial role,[9] recent evidence suggests that combustible cigarette smoking is associated with increased HDP risk.[10, 11] Another study also reported the risk of snuff use for preeclampsia, a severe phenotype of HDP.[20] Although the biological and genetic pathways (e.g., CYP2A6 and nicotine) underlying the associations observed in different phenotypes of HDP (e.g., preeclampsia and gestational hypertension) have not been elucidated,[21] HDP is recognized as a systemic disease attributable to placental circulatory dysfunction.[22] In experimental research, aerosol from HTPs was found to damage vascular endothelial function in rats.[5] Therefore, HDP risk associated with HTP use may involve acute and chronic vascular damage, irrespective of

combustible cigarette smoking. Furthermore, as concluded in a recent systematic review, smoking is a strong risk factor for LBW.[18] Thus, given the fact that HTPs are smoking devices, our observed results are in line with established knowledge.

Finally, the impression of HTPs as a healthy alternative is promoted by the advertising of HTPs.[4] Indeed, among currently pregnant women, approximately 4% of former combustible cigarette smokers reported smoking HTPs in the present study. This result might reflect a change from combustible cigarettes to HTP smoking during pregnancy. However, our findings imply that HTP use is at least not a healthy alternative. Evidence for unfavorable health outcomes regarding HTPs is still lacking, particularly in the young population of reproductive age. Insufficient health knowledge may have led to the current increase of HTP use among pregnant women, as reflected in our results and the latest statistics in Japan.[2, 3] However, the question remains as to how multidimensional factors of the COVID-19 pandemic (e.g., the infection, mental health, and socioeconomic factors) and the smoking behaviors of others (e.g., partners and family) affect the association between HTP use and perinatal risks. Our sequential series of the JACSIS study planned in 2021 may provide updates regarding the present results.

Our study had some limitations. First, our cross-sectional design does not allow to conclude causal mechanisms between HTP use and perinatal risks. However, the prevalence of HDP and HTP smokers were mostly parallel to the general population in Japan.[2, 3, 14] In addition, the incidence of HTP use did not differ between post-delivery and currently pregnant women in our study. Second, recall and reporting bias cannot be discarded. Because self-report-based smoking status among pregnant women tends to misclassify ever smokers as never smokers,[23] our estimates might be biased toward the null. Third, the perinatal clinical information was self-reported and not based on medical charts, thereby limiting the precision of the results. However, all participants were asked to base their responses on their

Maternal and Child Health Handbooks, a well-established home-base maternal and neonatal record during pregnancy.[16] Therefore, this limitation might not have affected our results or at least not largely. Despite these limitations, the strengths of the study included detailed information for HTPs, which covered all HTPs available during the study period. Additionally, this is the first report regarding the status of HTP use among pregnant women in Japan, and it highlights the potentially elevated maternal and neonatal risks associated with HTP use. Additionally, besides the present study, no other human studies to date have assessed the potential effect of the maternal use of new tobacco products (i.e., e-cigarette and HTP) on perinatal health.[24] Therefore, our findings shed light and motivate further investigations to estimate the life-threatening perinatal risks associated with new tobacco products.

In conclusion, the incidence of HTP use seems to exceed 10% among pregnant women, and HTP smoking may be associated with increased maternal and neonatal risks in Japan. With no doubt, smoking in reproductive age can cause unfavorable perinatal outcomes.[25] Hence, efforts should be made to investigate the risk of HTP use in reproductive age, and school-based tobacco prevention and cessation programs should be conducted regardless of product types to prevent life-threatening perinatal complications and deaths.

ACKNOWLEDGMENTS

We would like to thank Editage (www.editage.com) for English language editing.

FUNDING

This study was partly supported by Health, Labour and Welfare Sciences Research Grants (20FA1005) and the Japan Society for the Promotion of Science (JSPS KAKENHI JP18K17351).

261

262 **DATA AVAILABILITY STATEMENT**

263 The data that support the findings of this study are available on reasonable request. However,
264 restrictions apply to the availability of these data due to personal identification; research data
265 are not shared. If any person wishes to verify our data, they are most welcome to contact the
266 corresponding author.

267

268 **CONFLICT OF INTEREST**

269 The authors declare no potential conflicts of interest.

270

271 **AUTHOR CONTRIBUTIONS**

272 Conception and design: M Zaitzu, T Tabuchi; Development of methodology: M Zaitzu, Y
273 Hosokawa, S Okawa; Acquisition of data: S Okawa, A Hori, and T Tabuchi; Analysis and
274 interpretation of data: M Zaitzu, Y Hosokawa; Writing, review and/or revision of the
275 manuscript: All authors; Study supervision: T Tabuchi.

276

REFERENCES

- 1 Tabuchi T, Gallus S, Shinozaki T, et al. Heat-not-burn tobacco product use in Japan: its prevalence, predictors and perceived symptoms from exposure to secondhand heat-not-burn tobacco aerosol. *Tob Control* 2018;27:e25–e33.
- 2 Hori A, Tabuchi T, Kunugita N. Rapid increase in heated tobacco product (HTP) use from 2015 to 2019: from the Japan “Society and New Tobacco” Internet Survey (JASTIS). *Tob Control* 2020.
- 3 Odani S, Tabuchi T. Prevalence of heated tobacco product use in Japan: the 2020 JASTIS study. *Tob Control* 2021. Doi: 10.1136/tobaccocontrol-2020-056257
- 4 Hair EC, Bennett M, Sheen E, et al. Examining perceptions about IQOS heated tobacco product: consumer studies in Japan and Switzerland. *Tob Control* 2018;27(Suppl 1):s70–3.
- 5 Nabavizadeh P, Liu J, Havel CM, et al. Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke. *Tob Control* 2018;27(Suppl 1):s13–9.
- 6 Simonavicius E, McNeill A, Shahab L, et al. Heat-not-burn tobacco products: a systematic literature review. *Tob Control* 2019;28:582–94.
- 7 Duley L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol* 2009;33:130–7.
- 8 Hasegawa J, Sekizawa A, Tanaka H, et al. Current status of pregnancy-related maternal mortality in Japan: a report from the Maternal Death Exploratory Committee in Japan. *BMJ Open* 2016;6:e010304.
- 9 England L, Zhang J. Smoking and risk of preeclampsia: a systematic review. *Front Biosci* 2007;12:2471–83.

- 301 10 Hayashi K, Matsuda Y, Kawamichi Y, et al. Smoking during pregnancy increases risks of
302 various obstetric complications: a case-cohort study of the Japan Perinatal Registry
303 Network database. *J Epidemiol* 2011;21:61–6.
- 304 11 Tanaka K, Nishigori H, Watanabe Z, et al. Higher prevalence of hypertensive disorders of
305 pregnancy in women who smoke: the Japan environment and children’s study. *Hypertens*
306 *Res* 2019;42:558–66.
- 307 12 Rakuten Insight Inc. <https://insight.rakuten.co.jp/en/aboutus.html> (Accessed 11 Feb
308 2021).
- 309 13 Tabuchi T, Shinozaki T, Kunugita N, et al. Study profile: The Japan “Society and New
310 Tobacco” Internet Survey (JASTIS): A longitudinal internet cohort study of heat-not-burn
311 tobacco products, electronic cigarettes, and conventional tobacco products in Japan. *J*
312 *Epidemiol* 2019;29:444–50.
- 313 14. Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy:
314 prevalence, risk factors, predictors and prognosis. *Hypertens Res* 2017;40:213–20.
- 315 15 Fujimoto S, Nakamura Y, Ikeda M et al. Utilization of maternal and child health
316 handbook in Japan. *Nihon Koshu Eisei Zasshi* 2001;48:486–94.
- 317 16 Osaki K, Hattori T, Toda A, et al. Maternal and Child Health Handbook use for maternal
318 and child care: a cluster randomized controlled study in rural Java, Indonesia. *J Public*
319 *Health (Oxf)* 2019;41:170–82.
- 320 17 Igarashi A, Aida J, Kusama T, et al. Heated tobacco products have reached younger or
321 more affluent people in Japan. *J Epidemiol* 2021;31:187–93.
- 322 18. Abraham M, Alramadhan S, Iniguez C, et al. A systematic review of maternal smoking
323 during pregnancy and fetal measurements with meta-analysis. *PLOS ONE*
324 2017;12:e0170946.

- 325 19 Organization for Economic Cooperation and Development. OECD Family Database
326 [database on the Internet]. 2020.
327 https://www.oecd.org/els/family/CO_1_3_Low_birth_weight.pdf (accessed 28 Feb 2021).
- 328 20 England LJ, Levine RJ, Mills JL, et al. Adverse pregnancy outcomes in snuff users. *Am J*
329 *Obstet Gynecol* 2003;189:939–43.
- 330 21 Nakajima M, Yamagishi S, Yamamoto H, et al. Deficient cotinine formation from
331 nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. *Clin*
332 *Pharmacol Ther* 2000;67:57–69.
- 333 22 Yoshihara T, Zaitzu M, Kubota S, et al. Pool walking may improve renal function by
334 suppressing the renin-angiotensin-aldosterone system in healthy pregnant women. *Sci*
335 *Rep* 2020;10:2891.
- 336 23 Nishihama Y, Nakayama SF, Tabuchi T, et al. Determination of urinary cotinine cut-off
337 concentrations for pregnant women in the Japan environment and children’s study
338 (JECS). *Int J Environ Res Public Health* 2020;17.
- 339 24 Larcombe AN. Early-life exposure to electronic cigarettes: cause for concern. *Lancet*
340 *Respir Med* 2019;7:985–992.
- 341 25 Atrash HK, Johnson K, Adams M, et al. Preconception care for improving perinatal
342 outcomes: the time to act. *Matern Child Health J* 2006;10(Suppl):S3–S11.

343

344

FIGURE LEGEND

Figure 1. Odds ratio of ever heated tobacco product smokers with hypertensive disorders of pregnancy and low birth weight compared with never heated tobacco product smokers. Age was adjusted in model 1, and other covariates (combustible cigarette smoking, educational attainment, occupation, household income, and comorbidity) were additionally adjusted in model 2. The samples for each analysis in model 2 were as follows: n=494 (overall), n=370 (never combustible cigarette smokers), and n=124 (ever combustible cigarette smokers) for hypertensive disorders of pregnancy; and n=478 (overall), n=310 (never combustible cigarette smokers), and n=118 (ever combustible cigarette smokers) for low birth weight. Abbreviations: HTP, heated tobacco products; OR, odds ratio.

357 **Table 1. Characteristics of 558 post-delivery women and 365 currently pregnant women**

Characteristics	N (%) or mean (SD)			
	Post-delivery women		Currently pregnant women	
	Never HTP smokers	Ever HTP smokers	Never HTP smokers	Ever HTP smokers
Overall	<i>n=493</i>	<i>n=65</i>	<i>n=319</i>	<i>n=46</i>
Maternal and neonatal risk				
Hypertensive disorders of pregnancy	32 (6.5%)	9 (13.8%)*	NA	NA
Low birth weight <2500 g	44 (8.9%)	12 (18.5%)*	NA	NA
Preterm birth <37 weeks	19 (3.9%)	4 (6.2%)	NA	NA
Imminent preterm birth	82 (16.6%)	18 (27.7%)*	NA	NA
Age	32.4 (4.1)	30.9 (4.2)**	31.9 (4.3)	31.3 (4.7)
Ever combustible cigarette smoking	82 (16.6%)	55 (84.6%)*	54 (16.9%)	41 (89.1%)*
Educational attainment ≥13 years	410 (83.2%)	37 (56.9%)*	278 (87.1%)	31 (67.4%)*
Managerial workers	19 (3.9%)	5 (7.7%)	16 (5.0%)	2 (4.3%)
Comorbidity of hypertension or diabetes	35 (7.1%)	4 (6.2%)	4 (1.3%)	4 (8.7%)*
Household income	<i>n=436</i>	<i>n=58</i>	<i>n=263</i>	<i>n=41</i>
<200 million JPY	13 (3.0%)	3 (5.2%)	6 (2.3%)	1 (2.4%)
200 to <600 million JPY	200 (45.9%)	30 (51.7%)	115 (43.7%)	19 (46.3%)
≥600 million JPY	223 (51.1%)	25 (43.1%)	142 (54.0%)	21 (51.2%)
Never combustible cigarette smokers	<i>n=411</i>	<i>n=10</i>	<i>n=265</i>	<i>n=5</i>
Maternal and neonatal risk				
Hypertensive disorders of pregnancy	26 (6.3%)	1 (10.0%)	NA	NA
Low birth weight <2500 g	34 (8.3%)	3 (30.0%)*	NA	NA
Preterm birth <37 weeks	17 (4.1%)	0 (0%)	NA	NA
Imminent preterm birth	69 (16.8%)	3 (30.0%)	NA	NA
Age	32.2 (4.0)	33.3 (2.3)	31.7 (4.3)	30.2 (1.8)
Educational attainment ≥13 years	348 (84.7%)	7 (70%)	235 (88.7%)	4 (80.0%)
Managerial workers	16 (3.9%)	1 (10%)	14 (5.3%)	0 (0%)
Comorbidity of hypertension or diabetes	24 (5.8%)	0 (0%)	4 (1.5%)	0 (0%)
Household income	<i>n=361</i>	<i>n=9</i>	<i>n=219</i>	<i>n=5</i>

<200 million JPY	10 (2.8%)	0 (0%)	5 (2.3%)	0 (0%)
200 to <600 million JPY	160 (44.3%)	4 (44.4%)	97 (44.3%)	3 (60.0%)
≥600 million JPY	191 (52.9%)	5 (55.6%)	117 (53.45)	2 (40.0%)
Ever combustible cigarette smokers	<i>n</i> =82	<i>n</i> =55	<i>n</i> =54	<i>n</i> =41
Maternal and neonatal risk				
Hypertensive disorders of pregnancy	6 (7.3%)	8 (14.5%)	NA	NA
Low birth weight <2500 g	10 (12.2%)	9 (16.4%)	NA	NA
Preterm birth <37 weeks	2 (2.4%)	4 (7.3%)	NA	NA
Imminent preterm birth	13 (15.9%)	15 (27.3%)	NA	NA
Age	33.5 (4.3)	30.5 (4.3)***	32.9 (4.2)	31.4 (5.0)
Educational attainment ≥13 years	62 (75.6%)	30 (54.5%)**	43 (79.6%)	27 (65.9%)
Managerial workers	3 (3.7%)	4 (7.3%)	2 (3.7%)	2 (4.9%)
Comorbidity of hypertension or diabetes	11 (13.4%)	4 (7.3%)	0 (0%)	4 (9.8%)*
Household income	<i>n</i> =75	<i>n</i> =49	<i>n</i> =44	<i>n</i> =36
<200 million JPY	3 (4.0%)	3 (6.1%)	1 (2.3%)	1 (2.8%)
200 to <600 million JPY	40 (53.3%)	26 (53.1%)	18 (40.9%)	16 (44.4%)
≥600 million JPY	32 (42.7%)	20 (40.8%)	25 (56.8%)	19 (52.8%)

Abbreviation: HTP, heated tobacco product; NA, not applicable.

P*<0.05, *P*<0.01, ****P*<0.001 for chi-squared test or t-test.

Table 2. Detailed smoking status and use of heated tobacco products cross-classified according to combustible cigarette smoking status

Characteristics	HTP smoking status			
	Never	Former	Current	Total
Post-delivery women, <i>n</i> =558				
Never combustible cigarette smokers	411 (97.6%)	9 (2.1%)	1 (0.2%)	421 (100%)
Former combustible cigarette smokers	79 (64.2%)	32 (26.0%)	12 (9.8%)	123 (100%)
Current combustible cigarette smokers	3 (21.4%)	9 (64.3%)	2 (14.3%)	14 (100%)
Currently pregnant women, <i>n</i> =365				
Never combustible cigarette smokers	265 (98.1%)	5 (1.9%)	0 (0%)	270 (100%)
Former combustible cigarette smokers	54 (59.3%)	33 (36.3%)	4 (4.4%)	91 (100%)
Current combustible cigarette smokers	0 (0%)	4 (100%)	0 (0%)	4 (100%)

Abbreviation: HTP, heated tobacco product.

P*<0.05, *P*<0.01, ****P*<0.001 for chi-squared test or t-test.

OR for hypertensive disorders of pregnancy

Overall, *n*=558

Crude (ever HTP smokers vs. never HTP smokers)

Model 1 (ever HTP smokers vs. never HTP smokers)

Model 2 (ever HTP smokers vs. never HTP smokers)

Never combustible cigarette smokers, n=421

Crude (ever HTP smokers vs. never HTP smokers)

Model 1 (ever HTP smokers vs. never HTP smokers)

Model 2 (ever HTP smokers vs. never HTP smokers)

Ever combustible cigarette smokers, n=137

Crude (ever HTP smokers vs. never HTP smokers)

Model 1 (ever HTP smokers vs. never HTP smokers)

Model 2 (ever HTP smokers vs. never HTP smokers)

OR for low birth weight <2500 g

Overall, *n*=558

Crude (ever HTP smokers vs. never HTP smokers)

Model 1 (ever HTP smokers vs. never HTP smokers)

Model 2 (ever HTP smokers vs. never HTP smokers)

Never combustible cigarette smokers, n=421

Crude (ever HTP smokers vs. never HTP smokers)

Model 1 (ever HTP smokers vs. never HTP smokers)

Model 2 (ever HTP smokers vs. never HTP smokers)

Ever combustible cigarette smokers, n=137

Crude (ever HTP smokers vs. never HTP smokers)

Model 1 (ever HTP smokers vs. never HTP smokers)

Model 2 (ever HTP smokers vs. never HTP smokers)